Several other analysts have also issued reports on XYL. Zacks Investment Research upgraded Xylem from a hold rating to a buy rating and set a $84.00 price objective for the company in a report on Saturday, April 7th. BMO Capital Markets reissued a buy rating and set a $86.00 target price on shares of Xylem in a research report on Friday, February 2nd. Seaport Global Securities reissued a buy rating and set a $83.00 target price on shares of Xylem in a research report on Friday, February 2nd. Cowen reissued a buy rating and set a $80.00 target price on shares of Xylem in a research report on Tuesday, March 6th. Finally, Oppenheimer increased their target price on shares of Xylem to $82.00 and gave the stock an outperform rating in a research report on Friday, February 2nd. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $74.27.
Shares of NYSE:XYL opened at $75.49 on Tuesday. The company has a quick ratio of 1.41, a current ratio of 1.88 and a debt-to-equity ratio of 0.87. Xylem has a 1 year low of $49.71 and a 1 year high of $79.83. The firm has a market cap of $14,123.40, a P/E ratio of 31.45, a PEG ratio of 1.51 and a beta of 1.10.
In other news, insider Tomas Brannemo sold 1,151 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $76.41, for a total value of $87,947.91. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Curtis J. Crawford sold 7,948 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $71.77, for a total value of $570,427.96. Following the completion of the sale, the director now directly owns 55,245 shares in the company, valued at $3,964,933.65. The disclosure for this sale can be found here. Insiders have sold 21,105 shares of company stock worth $1,540,907 over the last three months. Company insiders own 0.81% of the company’s stock.
Large investors have recently modified their holdings of the company. Greenleaf Trust grew its position in shares of Xylem by 97.4% in the fourth quarter. Greenleaf Trust now owns 1,490 shares of the industrial products company’s stock valued at $102,000 after purchasing an additional 735 shares during the last quarter. Hanson & Doremus Investment Management acquired a new stake in shares of Xylem in the fourth quarter valued at about $126,000. UMB Bank N A MO acquired a new stake in shares of Xylem in the fourth quarter valued at about $205,000. JOYN Advisors Inc. acquired a new stake in shares of Xylem in the fourth quarter valued at about $205,000. Finally, Close Asset Management Ltd acquired a new stake in shares of Xylem in the fourth quarter valued at about $205,000. 85.91% of the stock is currently owned by institutional investors.
Xylem Inc engages in the design, manufacture, and service of engineered solutions for the water and wastewater applications. It operates through three segments: Water Infrastructure, Applied Water, and Measurement and Control Solutions. The Water Infrastructure segment offers various products, including water and wastewater pumps, and controls and systems, as well as filtration, disinfection, and biological treatment equipment under the Flygt, Godwin, Wedeco, Sanitaire, and Leopold names for the transportation, treatment, and testing of water and wastewater applications.
Receive News & Ratings for Xylem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xylem and related companies with MarketBeat.com's FREE daily email newsletter.